Weak raw material prices led to tepid earnings growth Our View Rossari’s reported ope...
Our View Rossari’s reported operating profits at Rs 546mn (+4%YoY; +1% QoQ) stood broadl...
Our View Rossari’s reported operating profits at Rs 542mn (+16%YoY; -4% QoQ) missed our ...
Margins stabilize as raw material price volatility subsides Our View Rossari’s report...
After margins, revenue has headwinds now! Rossari Biotech’s Q2FY23 result disappointed o...
Rossari Biotech is currently trading at Rs. 913.85, up by 5.35 points or 0.59% from its previous ...
Protecting margins; revenue growth tepid Rossari Biotech’s Q1FY23 result was a mixed pri...
Synergy from acquisitions aids growth Our View Rossari’s reported operating profits a...
Earnings growth aided by acquisitions Our View: Rossari’s reported ...
Strong volume growth; spreads compress Rossari Biotech’s Q2FY22 (standalone) EBITDA grow...
Key News DoT cuts bank guarantee requirement for telecom operators by 80% The Department of...
Value extraction from inorganic growth key Rossari Biotech’s Q1FY22 EBITDA growth of 56%...
MTF Stock Pick Buy Rossari Biotech Ltd For Target Rs. 1498 - HDFC Securi...
Rossari’s two acquisitions add 48% to EBITDA Rossari Biotech (Rossari) has announced two...
Inorganic growth is key to watch Rossari Biotech’s Q4FY21 EBITDA growth of 47% YoY to Rs...
Rossari Biotech is currently trading at Rs. 1299.15, up by 35.35 points or 2.80% from its previou...
Formulation and application specialists Rossari Biotech (Rossari) has competency in four chem...